PD Animal Models
Renovo’s Preclinical Model Systems Accelerate Drug Development for PD and other Neural Diseases
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder affecting millions of people around the world; roughly 1% of all those over 65 years of age. Currently diagnosis is based on motor symptoms (eg. resting tremor, postural instability), though non-motor symptoms are also observed. The motor symptoms of PD are attributed mainly to lack of dopamine neurotransmitter in the striatum. This, in turn, is caused by degeneration of the dopaminergic striatal fibers and the dopaminergic (DA) neurons of the substantia nigra pars compacta (SNpc). Spreading of alpha-synuclein and increased inflammation in the brain also contribute to PD pathology, supported by data from various animal models of PD. Renovo offers a portfolio of animal models that recapitulate the behavioral phenotype, neuropathology, and pathophysiology of PD, providing a diverse tool kit to evaluate neuroprotective and neurorestorative strategies. Renovo’s novel genetic mouse model replicates the slow degeneration of DA neurons along with other clinical and pathological features of PD to evaluate neuroprotective and neurorestorative therapies.
MPTP and 6-OHDA are the two most commonly used toxins models. Both compounds display selective toxicity towards dopaminergic neurons in the SNpc, and are well characterized models for the identification and development of new therapies.
In addition to the toxin-based models, Renovo is also working on a novel genetic model of PD currently under development.
Renovo’s novel genetic mouse model replicates the slow degeneration of DA neurons along with other clinical and pathological features of PD to evaluate neuroprotective and neurorestorative therapies.